Clinical improvements were achieved and maintained for up to 3 years among bDMARD-naïve patients with PsA who received bimekizumab.

Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.

Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis ...

AI Colton Scholar Dr. Jimin Tan earns ANRF grant to find PsA drug targets using machine learning and tissue analysis to ...

EULAR - The European Alliance of Associations for Rheumatology - recommends a treat-to-target approach, and suggests more ...

Two studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate, but ...

Two recent studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate2,3, but these did not ...

Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.

Enthesitis is a key, but often overlooked, feature of psoriatic arthritis. Learn how this inflammation at tendon and ligament attachment sites can affect diagnosis, symptoms, and treatment.

Alongside the data in PsA, UCB will present at EULAR new results demonstrating that Bimzelx delivered sustained clinical ...

UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) ...